BackAadi Bioscience Overview

Aadi Bioscience Net Income

Latest net income for AADI: $-80M, below the Healthcare sector average of $16B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Net Income

-$16.64M
68.37% YoY

As of Jun 2026

Annual Net Income (TTM)

-$79.83M
666.28% YoY

Trailing 12 months ending Jun 2026

Average Net Income (Comparison Companies)

Loading

Net Income History

Loading

Net Income Comparison

Loading

Annual Net Income Growth Rate (%)

Loading...

Annual Net Income Growth (Absolute)

Loading...

Aadi Bioscience (AADI) FAQ

Aadi Bioscience (AADI) currently reports a net income of $-80M as of June 2026. That compares with $-10M in the prior-year period — down 666.3% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Aadi Bioscience's net income history and peer comparisons.

Aadi Bioscience's net income decreased from $-10M to $-80M — a 666.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aadi Bioscience's net income of $-80M is lower than the Healthcare sector average of $16B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aadi Bioscience reported $-80M in net income as of June 2026. That compares with $-10M in the prior-year period — down 666.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-80M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Aadi Bioscience, and consider following AADI for alerts when major investors trade the stock.